# Disrupt CAD III Post-Approval Study (PAS)

> **NCT05021757** · — · COMPLETED · sponsor: **Shockwave Medical, Inc.** · enrollment: 1212 (actual)

## Conditions studied

- Coronary Artery Disease
- Myocardial Infarction

## Interventions

- **DEVICE:** Shockwave C2 Coronary IVL

## Key facts

- **NCT ID:** NCT05021757
- **Lead sponsor:** Shockwave Medical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-10
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 1212 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05021757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05021757, "Disrupt CAD III Post-Approval Study (PAS)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05021757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*